The pharmaceutical industry welcomes the policy support and related sectors may be entering a long-term strategic investment window.

On April 15th, the A-share pharmaceutical and biotech sector collectively strengthened, with a net inflow of over 4.3 billion yuan of main funds for the entire day. On the news front, on April 15th, the State Council Information Office held a routine policy briefing. He Yaqiong, director of the Consumer Industry Department of the Ministry of Industry and Information Technology, stated that the ministry is preparing the "13th Five-Year Plan" for the pharmaceutical industry. A research report from Aijian Securities believes that the pharmaceutical sector is entering a long-term allocation window, and they continue to be optimistic about the industrial trend of Chinese innovative drugs going global in 2026. In the short term, they are focusing on investment opportunities in price-increasing varieties such as gloves and vitamins, while in the long term, the trend of innovation and development in the Chinese pharmaceutical industry remains unchanged, and long-term layout opportunities are expected after market consolidation.